Furmonertinib, characterized by its high selectivity and safety profile as a third-generation EGFR–tyrosine kinase inhibitor (TKI), exhibits minimal adverse events compared with other EGFR–TKIs, and the incidence rate of erythema is only 7%.5 Therefore, furmonertinib may be a potential treatment strategy and requires further clinical evaluation. This evidence concerns the gene EGFR and Erythema.